### Interactions with CAB/RPV long acting injections

Pharmacokinetic interactions shown are mostly with RPV. QT interactions shown are with RPV.

### Interactions with Lenacapavir

Residual LEN may affect exposure of sensitive CYP3A4 substrates initiated within 9 months after stopping subcutaneous LEN.

### Interactions with Ibalizumab

None

### Colour Legend

- No clinically significant interaction expected.
- These drugs should not be coadministered.
- Potential interaction which may require a dose adjustment or close monitoring.
- Potential interaction predicted to be of weak intensity.
- No a priori dosage adjustment is recommended.

### Text Legend

- ↑ Potential increased exposure of the hormone
- ↔ No significant effect

### Notes

- **a** The clinical significance of increased exposure in terms of overall risk of deep vein thrombosis, pulmonary embolism, stroke and myocardial infarction in postmenopausal women receiving substitution hormones is unknown. HRT should be used at the lowest effective dose and for the shortest duration consistent with treatment goals and risks for individual women. Postmenopausal women should be re-evaluated periodically as clinically appropriate to determine if treatment is still necessary.
- **b** Monitor for signs of hormone deficiency.
- **c** Coadministration is contraindicated in the US product label due to the potential for hyperkalaemia. The European product label recommends clinical monitoring for hyperkalaemia.
- **d** Clinical monitoring is recommended due to the potential risk for hyperkalaemia.
- **e** No effect on progesterin, but potential increase in exposure of conjugated estrogens or estradiol.

### Abbreviations

- ATV/r: Atazanavir/ritonavir
- DRV/r: Darunavir/cobicistat/ritonavir
- LPV/r:洛匹那韦/ ritonavir
- DOR: Doravirine
- EFV: Efavirenz
- ETV: Etravirine
- NVP: Nevirapine
- RPV: Rilpivirine
- BIC: Bicapridine
- FTC: Emtricitabine
- DF: Tenofovir DF (TDF) or Zidovudine (ZDV)
- EVG: Elvitegravir
- FTC/TAF: F/TAF
- EVG/c/FTC/TAF: EVG/c/ FTC/TAF
- EVG/c/FTDF: EVG/c/FTDF
- RAL: Raltegravir
- FTC: Emtricitabine
- TAF: Tenofovir DF

---

**HRT Treatment Selector**

Charts reviewed December 2023. Full information available at [www.hiv-druginteractions.org](http://www.hiv-druginteractions.org)